Construction of Retroviral Vectors with Improved Safety, Gene Expression, and Versatility

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1998 Jan 28

PMID 9444992

Citations 13

Authors

S H Kim

S S Yu

J S Park

P D Robbins

C S An

S Kim

Affiliations

Soon will be listed here.

Abstract

Murine leukemia virus (MLV)-based retroviral vectors are the most frequently used gene delivery vehicles. However, the current vectors are still not fully optimized for gene expression and viral titer, and many genetic and biochemical features of MLV-based vectors are poorly understood. We have previously reported that the retroviral vector MFG, where the gene of interest is expressed as a spliced mRNA, is superior in the level of gene expression with respect to other vectors compared in the study. As one approach to developing improved retroviral vectors, we have systematically performed mutational analysis of the MFG retroviral vector. We demonstrated that the entire gag coding sequence, together with the immediate upstream region, could be deleted without significantly affecting viral packaging or gene expression. To our knowledge, this region is included in all currently available retroviral vectors. In addition, almost the entire U3 region could be replaced with the heterologous human cytomegalovirus immediately-early promoter without deleterious effects. We could also insert internal ribosome entry sites (IRES) and multicloning sites into MFG without adverse effects. Based on these observations, we have constructed a series of new, improved retroviral constructs. These vectors produced viral titers comparable to MFG, expressed high levels of gene expression, and stably transferred genes to the target cells. Our vectors are more convenient to use because of the presence of multicloning sites and IRESs, and they are also more versatile because they can be readily converted to various applications. Our results have general implications regarding the design and development of improved retroviral vectors for gene therapy.

Citing Articles

Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors.

Fan J, Das J, Xiong X, Chen H, Song J Front Oncol. 2021; 10:574860.

PMID: 33489881 PMC: 7815927. DOI: 10.3389/fonc.2020.574860.

Gammaretroviral vectors: biology, technology and application.

Maetzig T, Galla M, Baum C, Schambach A Viruses. 2011; 3(6):677-713.

PMID: 21994751 PMC: 3185771. DOI: 10.3390/v3060677.

DNA as therapeutics; an update.

Saraswat P, Soni R, Bhandari A, Nagori B Indian J Pharm Sci. 2010; 71(5):488-98.

PMID: 20502565 PMC: 2866338. DOI: 10.4103/0250-474X.58169.

Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.

Schambach A, Baum C DNA Repair (Amst). 2007; 6(8):1187-96.

PMID: 17482894 PMC: 2128767. DOI: 10.1016/j.dnarep.2007.03.017.

A novel gene transfer strategy that combines promoter and transgene activities for improved tumor cell inhibition.

Strauss B, Bajgelman M, Costanzi-Strauss E Cancer Gene Ther. 2005; 12(12):935-46.

PMID: 15905860 DOI: 10.1038/sj.cgt.7700846.

References

Valerio D, Einerhand M, Wamsley P, Bakx T, Li C, Verma I . Retrovirus-mediated gene transfer into embryonal carcinoma and hemopoietic stem cells: expression from a hybrid long terminal repeat. Gene. 1989; 84(2):419-27. DOI: 10.1016/0378-1119(89)90516-7. View

Faustinella F, Kwon H, Serrano F, Belmont J, Caskey C, Aguilar-Cordova E . A new family of murine retroviral vectors with extended multiple cloning sites for gene insertion. Hum Gene Ther. 1994; 5(3):307-12. DOI: 10.1089/hum.1994.5.3-307. View

Alford R, Honda S, Lawrence C, Belmont J . RNA secondary structure analysis of the packaging signal for Moloney murine leukemia virus. Virology. 1991; 183(2):611-9. DOI: 10.1016/0042-6822(91)90990-s. View

Moore K, Scarpa M, Kooyer S, Utter A, Caskey C, Belmont J . Evaluation of lymphoid-specific enhancer addition or substitution in a basic retrovirus vector. Hum Gene Ther. 1991; 2(4):307-15. DOI: 10.1089/hum.1991.2.4-307. View

Morgan R, Couture L, Elroy-Stein O, Ragheb J, Moss B, Anderson W . Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res. 1992; 20(6):1293-9. PMC: 312173. DOI: 10.1093/nar/20.6.1293. View

Ohashi T, Boggs S, Robbins P, Bahnson A, Patrene K, Wei F . Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector. Proc Natl Acad Sci U S A. 1992; 89(23):11332-6. PMC: 50544. DOI: 10.1073/pnas.89.23.11332. View

Takeuchi Y, Cosset F, LACHMANN P, Okada H, Weiss R, Collins M . Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol. 1994; 68(12):8001-7. PMC: 237263. DOI: 10.1128/JVI.68.12.8001-8007.1994. View

Kasahara N, DOZY A, Kan Y . Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science. 1994; 266(5189):1373-6. DOI: 10.1126/science.7973726. View

Zitvogel L, Tahara H, Cai Q, Storkus W, Muller G, Wolf S . Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum Gene Ther. 1994; 5(12):1493-506. DOI: 10.1089/hum.1994.5.12-1493. View

10.

Kabat D . Targeting retroviral vectors to specific cells. Science. 1995; 269(5222):417. DOI: 10.1126/science.7618110. View

11.

Riviere I, Brose K, Mulligan R . Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci U S A. 1995; 92(15):6733-7. PMC: 41403. DOI: 10.1073/pnas.92.15.6733. View

12.

Marshall E . Gene therapy's growing pains. Science. 1995; 269(5227):1050, 1052-5. DOI: 10.1126/science.7652552. View

13.

Ali M, Lemoine N, Ring C . The use of DNA viruses as vectors for gene therapy. Gene Ther. 1994; 1(6):367-84. View

14.

Cosset F, Takeuchi Y, Battini J, Weiss R, Collins M . High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol. 1995; 69(12):7430-6. PMC: 189680. DOI: 10.1128/JVI.69.12.7430-7436.1995. View

15.

Boggs S, Patrene K, Mueller G, Evans C, Doughty L, Robbins P . Prolonged systemic expression of human IL-1 receptor antagonist (hIL-1ra) in mice reconstituted with hematopoietic cells transduced with a retrovirus carrying the hIL-1ra cDNA. Gene Ther. 1995; 2(9):632-8. View

16.

Lee S, Kim S, Robbins P, Kim B . Optimization of environmental factors for the production and handling of recombinant retrovirus. Appl Microbiol Biotechnol. 1996; 45(4):477-83. DOI: 10.1007/BF00578459. View

17.

Byun J, Kim S, Kim J, Yu S, Robbins P, Yim J . Analysis of the relative level of gene expression from different retroviral vectors used for gene therapy. Gene Ther. 1996; 3(9):780-8. View

18.

Krall W, Skelton D, Yu X, Riviere I, Lehn P, Mulligan R . Increased levels of spliced RNA account for augmented expression from the MFG retroviral vector in hematopoietic cells. Gene Ther. 1996; 3(1):37-48. View

19.

Byun J, Kim J, Kim S, Yim J, Robbins P, Kim S . A simple and rapid method for the determination of recombinant retrovirus titer by G418 selection. Gene Ther. 1996; 3(11):1018-20. View

20.

Shinnick T, Lerner R, Sutcliffe J . Nucleotide sequence of Moloney murine leukaemia virus. Nature. 1981; 293(5833):543-8. DOI: 10.1038/293543a0. View